Improved immune responses against zika virus after sequential dengue and zika virus infection in humans

Fecha de publicación: 01/01/2018

Autores organización

• 

  Felix Giovanni Delgado Tiria

  Autor

• 

  Jaime Eduardo Castellanos Parra

  Autor

• Maria Consuelo Romero Sanchez

  Autor

Autores

• Torres K.I.
• Simon-Lorière E.
• Sakuntabhai A.
• Roth C.

Unidades de investigación

• Grupo de Inmunología celular y molecular Universidad El Bosque (InmuBo)

  Investigador

  Maria Consuelo Romero Sanchez

• Grupo de Virología

  

  Investigador

  Jaime Eduardo Castellanos Parra

Resumen

The high levels of dengue-virus (DENV) seroprevalence in areas where the Zika virus (ZIKV) is circulating and the cross-reactivity between these two viruses have raised concerns on the risk of increased ZIKV disease severity for patients with a history of previous DENV infections. To determine the role of DENV preimmunity in ZIKV infection, we analyzed the T-and B-cell responses against ZIKV in donors with or without previous DENV infection. Using peripheral blood mononuclear cells (PBMCs) from donors living in an endemic area in Colombia, we have identified, by interferon (IFN)-? enzyme-linked immunospot (ELISPOT) assay, most of the immunodominant ZIKV T-cell epitopes in the nonstructural (NS) proteins NS1, NS3, and NS5. Analyses of the T-and B-cell responses in the same donors revealed a stronger T-cell response against peptides conserved between DENV and ZIKV, with a higher level of ZIKV-neutralizing antibodies in DENV-immune donors in comparison with DENV-naïve donors. Strikingly, the potential for antibody-mediated enhancement of ZIKV infection was reduced in donors with sequential DENV and ZIKV infection in comparison with donors with DENV infection only. Altogether, these data suggest that individuals with DENV immunity present improved immune responses against ZIKV. © 2018 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

• Adaptive Immunity; Antibodies, Neutralizing; Antibodies, Viral; B-Lymphocytes; Colombia; Dengue; Humans; Interferon-gamma; Leukocytes, Mononuclear; T-Lymphocytes; Zika Virus; Zika Virus Infection; epitope; gamma interferon; HLA antigen class 1; HLA antigen class 2; immunoglobulin G; immunoglobulin M; neutralizing antibody; nonstructural protein 1; nonstructural protein 3; nonstructural protein 5; virus vaccine; gamma interferon; neutralizing antibody; virus antibody; adult; allele; antibody dependent enhancement; antibody specificity; Article; B lymphocyte activation; C6/36 cell line; cellular immunity; cohort analysis; controlled study; cross reaction; dengue; Dengue virus 1; Dengue virus 2; Dengue virus 3; Dengue virus 4; density gradient centrifugation; DNA isolation; enzyme linked immunosorbent assay; enzyme linked immunospot assay; female; flow cytometry; HLA typing; human; human cell; K-562 cell line; major clinical study; male; nonhuman; peripheral blood mononuclear cell; quanti